The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database.
 
Christophe Tournigand
Honoraria - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer
Research Funding - Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche
 
Guilherme Lopes
No Relationships to Disclose
 
Curtis L. Olswold
No Relationships to Disclose
 
Richard Adams
Honoraria - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; SERVIER; SERVIER; SERVIER; SERVIER
Speakers' Bureau - Merck Serono; Merck Serono; Merck Serono; Merck Serono
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; SERVIER; SERVIER; SERVIER; SERVIER
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Aimmune; Aimmune; Aimmune; Aimmune; Alnylam; Alnylam; Alnylam; Alnylam; Biomarin; Biomarin; Biomarin; Biomarin; Bluebird Bio; Bluebird Bio; Bluebird Bio; Bluebird Bio; Cochlear; Cochlear; Cochlear; Cochlear; CSL Limited; CSL Limited; CSL Limited; CSL Limited; Dova Pharmaceuticals; Dova Pharmaceuticals; Dova Pharmaceuticals; Dova Pharmaceuticals; GW Pharmaceuticals; GW Pharmaceuticals; GW Pharmaceuticals; GW Pharmaceuticals; Juno Therapeutics; Juno Therapeutics; Juno Therapeutics; Juno Therapeutics; Kiadis Pharma; Kiadis Pharma; Kiadis Pharma; Kiadis Pharma; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Sage Therapeutics; Sage Therapeutics; Sage Therapeutics; Sage Therapeutics; TherapeuticsMD; TherapeuticsMD; TherapeuticsMD; TherapeuticsMD; Vertex; Vertex; Vertex; Vertex
Honoraria - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Halozyme; Halozyme; Halozyme; Halozyme; Merck Serono; Merck Serono; Merck Serono; Merck Serono; pfizer; pfizer; pfizer; pfizer; Specialised Therapeutics; Specialised Therapeutics; Specialised Therapeutics; Specialised Therapeutics; Targovax; Targovax; Targovax; Targovax
Consulting or Advisory Role - Halozyme; Halozyme; Halozyme; Halozyme; Lipotek; Lipotek; Lipotek; Lipotek; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pfizer; Pfizer; Pfizer; Pfizer; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Targovax; Targovax; Targovax; Targovax
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Specialised Therapeutics (Inst); Specialised Therapeutics (Inst); Specialised Therapeutics (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Deciphera; Deciphera; Deciphera; Deciphera; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst)
 
Leonard B. Saltz
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Richard M. Goldberg
Honoraria - Amgen; Amgen; Amgen; Amgen
Consulting or Advisory Role - Merck; Merck; Merck; Merck; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Merck; Merck; Merck; Merck; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA
 
Herbert Hurwitz
Employment - Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Stock and Other Ownership Interests - Roche; Roche; Roche; Roche
Consulting or Advisory Role - Acceleron Pharma; Acceleron Pharma; Acceleron Pharma; Acceleron Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Incyte; Incyte; Incyte; Incyte; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; OncoMed; OncoMed; OncoMed; OncoMed; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); NCI (Inst); NCI (Inst); NCI (Inst); NCI (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Regeneron (Inst); Regeneron (Inst); Regeneron (Inst); Regeneron (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Methods for treatment of Hand Foot Syndrome; Methods for treatment of Hand Foot Syndrome; Methods for treatment of Hand Foot Syndrome; Methods for treatment of Hand Foot Syndrome
 
Carsten Bokemeyer
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Servier/Pfizer; Servier/Pfizer; Servier/Pfizer; Servier/Pfizer
Consulting or Advisory Role - AOK Health Insurance; AOK Health Insurance; AOK Health Insurance; AOK Health Insurance; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; GSO; GSO; GSO; GSO; Hexal; Hexal; Hexal; Hexal; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Mundipharma; Mundipharma; Mundipharma; Mundipharma; Sanofi; Sanofi; Sanofi; Sanofi
Research Funding - several companies in coooperation for clincal studies and for preclinical laboratory work (at my institution more than 100 ongoing reserach projects) (Inst); several companies in coooperation for clincal studies and for preclinical laboratory work (at my institution more than 100 ongoing reserach projects) (Inst); several companies in coooperation for clincal studies and for preclinical laboratory work (at my institution more than 100 ongoing reserach projects) (Inst); several companies in coooperation for clincal studies and for preclinical laboratory work (at my institution more than 100 ongoing reserach projects) (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi
 
Charles S. Fuchs
Leadership - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health
Consulting or Advisory Role - Agios; Agios; Agios; Agios; Bain Capital; Bain Capital; Bain Capital; Bain Capital; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Dicerna; Dicerna; Dicerna; Dicerna; Entrinsic Health; Entrinsic Health; Entrinsic Health; Entrinsic Health; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; KEW; KEW; KEW; KEW; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merrimack; Merrimack; Merrimack; Merrimack; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics; Unum Therapeutics
 
Benoist Chibaudel
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Servier; Servier; Servier; Servier
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi
 
Axel Grothey
Honoraria - Aptitude Health; Aptitude Health; Aptitude Health; Aptitude Health; Elsevier; Elsevier; Elsevier; Elsevier; IMEDEX; IMEDEX; IMEDEX; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst)
Research Funding - Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
 
Aimery De Gramont
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
 
Qian Shi
No Relationships to Disclose